Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma
Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma
复制标题
DOI：
10.3892/mco.2020.2047
复制
发表时间：
2020-07-01
影响因子：
1.2
通讯作者：
Takayama, Wataru
中科院分区：
文献类型：
--
作者：
Iwatate, Yosuke;Hoshino, Isamu;Takayama, Wataru
p16基因，也称为CDKN 2A、INK 4A或CDK 4 I，及其已知为细胞周期抑制剂和肿瘤抑制剂的产物已被报道在各种人类肿瘤类型中发生改变。使用免疫组织化学（IHC）已表明改变的p16与阴性p16表达相关。然而，它与预后的关系仍然存在争议，因为以前的研究结果不一致。本研究旨在探讨原发性胰腺导管腺癌（PDAC）中p16蛋白表达水平与临床病理特征及预后的关系。从2013年1月至2017年12月，获得了103例接受选择性胰腺切除术的PDAC患者的组织，并通过IHC评估了p16表达。p16蛋白表达与临床病理因素无相关性（P>0.05）。值得注意的是，使用Kaplan-Meier方法，IHC上阴性p16表达与不良预后无显著相关性。
The p16 gene, which is also known asCDKN2A, INK4A, or CDK4I, and its products that are known to be cell cycle inhibitors and tumor suppressors have been reported to be altered in various human tumor types. Altered p16 has been indicated to be correlated with negative p16 expression using immunohistochemistry (IHC). However, its association with the prognosis remains controversial because the findings of previous studies are inconsistent. The current study evaluated the relationship between the expression levels of p16 and the clinicopathological features associated with prognosis in patients with primary pancreatic ductal adenocarcinomas (PDACs). From January 2013 to December 2017, tissues of 103 PDAC patients who had undergone elective pancreatic resection were obtained and assessed for p16 expression by IHC. No correlation was observed between p16 status and clinicopathological factors (P>0.05). Notably, negative p16 expression on IHC was not significantly associated with poor prognosis using the Kaplan-Meier method.